We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression.
- Authors
Qadir, Abdul; Khalid, Zurqa; Theba, Fareha Kashan; Ali, Muhammad Mujtaba; Asif, Mahayrookh; Rizvi, Fatima
- Abstract
Lung cancer is the most typical form of cancer that results in death worldwide. Patients with non-small cell lung cancer (NSCLC) have an around 15% survival rate despite of advancement in cancer treatment. This study aimed to evaluate the combined effect of celecoxib and bevacizumab on NSCLC using A549 cells as an in vitro model. The A549 cells were culture and treated with celecoxib, bevacizumab and their combination and the cell proliferation was assessed using MTT assay, whereas cell apoptosis was analyzed using flowcytometry. The effects on the apoptotic genes were examined using western blotting, while qPCR was used for analyzing the VEGF and MMP-9 expression. Celecoxib, bevacizumab and their combination exhibited a dose dependent inhibition (p<0.001). The rate of apoptosis was 14.1% and 26.5% but when the two drugs were combined, the rate of apoptosis was significantly increased due to synergism by 52.2% (p<0.001). Western blotting displayed that co-treatment significantly upregulated proapoptotic genes (caspase-3 and -9) and downregulated anti-apoptotic gene (Bcl-2) (p<0.001). Additionally, VEGF and MMP-9 expression were both significantly reduced with co-treatment compared to the control (p<0.001). Celecoxib combined with bevacizumab synergistically inhibited NSCLC by inducing apoptosis and modulating VEGF and MMP-9 expression.
- Subjects
NON-small-cell lung carcinoma; BEVACIZUMAB; MATRIX metalloproteinases; CELECOXIB; APOPTOSIS
- Publication
Pakistan Journal of Pharmaceutical Sciences, 2023, Vol 36, Issue 2, p501
- ISSN
1011-601X
- Publication type
Article
- DOI
10.36721/PJPS.2023.36.2.REG.501-506.1